Profile data is unavailable for this security.
About the company
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
- Revenue in USD (TTM)578.20m
- Net income in USD217.56m
- Incorporated2006
- Employees181.00
- LocationCatalyst Pharmaceuticals Inc355 ALHAMBRA CIRCLE, SUITE 801CORAL GABLES 33134United StatesUSA
- Phone+1 (305) 529-2522
- Fax+1 (302) 636-5454
- Websitehttps://catalystpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phibro Animal Health Corp | 1.46bn | 92.09m | 2.12bn | 2.48k | 23.17 | 6.37 | 14.83 | 1.45 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
| Tarsus Pharmaceuticals Inc | 366.10m | -81.16m | 2.58bn | 323.00 | -- | 7.70 | -- | 7.05 | -2.01 | -2.01 | 8.99 | 7.89 | 0.8039 | 7.39 | 7.19 | 1,133,437.00 | -17.82 | -33.35 | -22.30 | -37.21 | 93.26 | -- | -22.17 | -125.04 | 4.25 | -- | 0.1774 | -- | 948.62 | -- | 14.97 | -- | 106.47 | -- |
| Apellis Pharmaceuticals Inc | 1.02bn | 44.99m | 2.75bn | 705.00 | 73.08 | 6.84 | 58.84 | 2.70 | 0.297 | 0.297 | 8.03 | 3.17 | 1.04 | 0.9298 | 3.25 | 1,441,698.00 | 4.59 | -61.31 | 6.04 | -76.53 | 88.85 | 86.49 | 4.43 | -157.26 | 3.10 | 2.51 | 0.5313 | -- | 97.02 | -- | 62.57 | -- | -24.96 | -- |
| Supernus Pharmaceuticals Inc | 681.54m | -19.12m | 2.92bn | 674.00 | -- | 2.77 | 43.97 | 4.28 | -0.3408 | -0.3408 | 12.09 | 18.38 | 0.4934 | 0.959 | 4.30 | 1,011,185.00 | -1.38 | 4.25 | -1.79 | 5.58 | 89.91 | 87.90 | -2.80 | 10.41 | 1.56 | -- | 0.00 | -- | 8.94 | 11.00 | 5,512.84 | -8.16 | -23.33 | -- |
| Catalyst Pharmaceuticals Inc | 578.20m | 217.56m | 2.99bn | 181.00 | 14.20 | 3.26 | 11.71 | 5.17 | 1.71 | 1.71 | 4.55 | 7.47 | 0.6341 | 3.45 | 7.02 | 3,194,453.00 | 23.86 | 24.62 | 27.38 | 28.82 | 85.68 | 85.77 | 37.63 | 31.73 | 6.40 | -- | 0.00 | 0.00 | 23.49 | 36.89 | 129.50 | 38.75 | 95.70 | -- |
| Twist Bioscience Corp | 391.56m | -76.58m | 3.01bn | 979.00 | -- | 6.60 | -- | 7.69 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Prestige Consumer Healthcare Inc | 1.10bn | 186.50m | 3.16bn | 600.00 | 17.66 | 1.73 | 14.59 | 2.86 | 3.78 | 3.78 | 22.38 | 38.66 | 0.3234 | 3.07 | 6.17 | 1,839,343.00 | 5.47 | 4.13 | 5.67 | 4.30 | 56.12 | 56.31 | 16.90 | 13.13 | 1.93 | 8.28 | 0.3657 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Arcutis Biotherapeutics Inc | 317.93m | -44.32m | 3.17bn | 342.00 | -- | 19.68 | -- | 9.96 | -0.3545 | -0.3545 | 2.49 | 1.31 | 0.7866 | 1.75 | 3.63 | 929,616.90 | -10.97 | -61.20 | -16.53 | -68.48 | 89.96 | -- | -13.94 | -406.29 | 3.28 | -2.61 | 0.407 | -- | 229.74 | -- | 46.58 | -- | 77.12 | -- |
| Liquidia Corp | 69.22m | -121.85m | 3.32bn | 157.00 | -- | 150.39 | -- | 48.01 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 597.97m | 35.92m | 3.44bn | 315.00 | 101.19 | 6.39 | 91.94 | 5.75 | 0.4484 | 0.4484 | 7.81 | 7.10 | 0.9435 | 2.13 | 15.61 | 1,898,327.00 | 5.67 | -8.31 | 6.85 | -9.52 | 87.52 | -- | 6.01 | -17.33 | 3.51 | -- | 0.00 | -- | 56.60 | -- | -406.68 | -- | -38.71 | -- |
| Ligand Pharmaceuticals Inc | 251.23m | 48.58m | 3.62bn | 68.00 | 88.47 | 3.80 | 43.70 | 14.40 | 2.08 | 2.08 | 12.77 | 48.34 | 0.2066 | 1.01 | 5.47 | 3,694,603.00 | 4.00 | 1.82 | 4.09 | 1.92 | 94.27 | 82.57 | 19.34 | 10.30 | 24.30 | -- | 0.3192 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| ADMA Biologics Inc | 488.56m | 209.45m | 3.83bn | 677.00 | 18.98 | 8.89 | 17.61 | 7.84 | 0.8476 | 0.8476 | 1.98 | 1.81 | 1.02 | 1.20 | 5.20 | 721,652.90 | 43.67 | -2.99 | 48.83 | -3.39 | 54.71 | 34.09 | 42.87 | -4.56 | 3.65 | 26.62 | 0.1438 | -- | 65.15 | 70.79 | 800.00 | -- | 17.60 | -- |
Data as of Feb 13 2026. Currency figures normalised to Catalyst Pharmaceuticals Inc's reporting currency: US Dollar USD
40.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 16.30m | 13.26% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.49m | 6.09% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 6.91m | 5.62% |
| Fundsmith LLPas of 30 Sep 2025 | 3.36m | 2.74% |
| American Century Investment Management, Inc.as of 31 Dec 2025 | 3.03m | 2.46% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.90m | 2.36% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 2.71m | 2.21% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 2.65m | 2.16% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 2.34m | 1.90% |
| Royce & Associates LPas of 31 Dec 2025 | 1.91m | 1.56% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
